Horizon shells out $510M for access to gout med Krystexxa

Horizon ($HZNP) may have quit on its hostile pursuit of California's Depomed ($DEPO), but that doesn't mean it's quit on dealmaking altogether. On the contrary, on Friday it announced an all-cash, $510 million deal for Crealta, which owns Krystexxa, a treatment for chronic refractory gout. It's not the first time the med has changed hands recently; in late December, near-bankrupt Savient inked a pact to sell itself and its assets to Crealta for $120.4 million. Release | More